The Neuroendovascular Coil Market size is estimated to reach $1,151.3 million by 2027, growing at a CAGR of 4.3% during the forecast period 2022-2027. Neuroendovascular coiling involves a minimally invasive endovascular treatment that is carried out to obstruct the blood flow in a blood vessel in the brain. It is vital to treat an aneurysm, a bulge brought about by weakness in the wall of a blood vessel, which can break owing to increasing pressure and bleed into the brain. Neuroendovascular coils are utilized as a substitute efficient treatment for surgical clipping in an aneurysm. The endovascular coiling treatment is normally carried out under general anesthesia by a neurosurgeon or an interventional neuroradiologist applying fluoroscopic imaging guidance. The decreased cost acquired and the reduced risk for patients is set to drive the Neuroendovascular Coil Market. The soaring progress in neuroendovascular technology in terms of shape, length and bioactivity, the rising application of endovascular coiling for treating unruptured intracranial aneurysms (UIAs) and the surging financing of different key players in the launch of technologically progressive products are set to propel the growth of the Neuroendovascular Coil Industry during the forecast period 2022-2027. This represents the Neuroendovascular Coil Industry Outlook.
Neuroendovascular Coil Market Report Coverage
The “Neuroendovascular Coil Market Report - Forecast (2022-2027)” by Industry ARC, covers an in-depth analysis of the following segments in the Neuroendovascular Coil Market.
- Geographically, North America (Neuroendovascular Coil market share) accounted for the highest revenue share in 2021 and it is poised to dominate the market over the period 2022-2027 owing to the extensive accessibility of technologically progressive coils and surging companion investigations on unruptured intracranial aneurysms (UIAs) in the North American region.
- Neuroendovascular Coil Market growth is being driven by the rising frequency of Unruptured Intracranial Aneurysms (UIA) detection. However, the hazard of complexity in neuroendovascular processes and the solid competition amidst existing neuroendovascular coil makers are some of the major factors hampering the growth of the Neuroendovascular Coil Market.
- Neuroendovascular Coil Market Detailed Analysis on the Strength, Weaknesses and Opportunities of the prominent players operating in the market will be provided in the Neuroendovascular Coil Market report.
Neuroendovascular Coil Market: Market Share (%) by Region, 2021
For More Details on This Report - Request for Sample
Neuroendovascular Coil Market Segment Analysis - by Product Type
The Neuroendovascular Coil Market based on product type can be further segmented into Guglielmi Detachable Coils (GDCs) and Matrix Cells. The Guglielmi Detachable Coils (GDCs) Segment held the largest Neuroendovascular Coil market share in 2021. This growth is owing to the surging demand for Guglielmi Detachable Coils (GDCs) from end users. Guglielmi Detachable Coils (GDCs) are flexible and are effortlessly accessible as 2D and 3D coils. The beneficial capability of being effortlessly repositioned with a better ability to regulate detachment tracking and visibility with fluoroscopic imaging is further propelling the growth of the Guglielmi Detachable Coils (GDCs) segment. Furthermore, the Guglielmi Detachable Coils (GDCs) segment is estimated to grow with the fastest CAGR of 5.1% during the forecast period 2022-2027 owing to the increasing count of neuroendovascular procedures and the expanding population of the elderly worldwide.
Neuroendovascular Coil Market Segment Analysis - by End-user
The Neuroendovascular Coil Market based on end-user can be further segmented into Hospitals, Ambulatory Surgical Centers (ASCs), Stroke Centers and Others. The Hospitals Segment held the largest Neuroendovascular Coil market share in 2021. This growth is owing to the increasing inclination of patients toward hospitals for the diagnosis of conditions like intracranial aneurysms and tumor surgery. The existence of progressive infrastructure and the effortless availability of qualified and skilled physicians and multidisciplinary teams in hospitals are further propelling the growth of this segment.
Furthermore, the Stroke Centers segment is estimated to grow with the fastest CAGR of 5.8% during the forecast period 2022-2027 owing to the extensive neuroendovascular treatment of acute stroke conditions during the Coronavirus (COVID-19) Pandemic and neuroendovascular coils being utilized as an alternate efficient treatment to surgical clipping in an aneurysm
Neuroendovascular Coil Market Segment Analysis - by Geography
The Neuroendovascular Coil Market based on geography can be further segmented into North America, Europe, Asia-Pacific, South America and the Rest of the World. North America (Neuroendovascular Coil Market) held the largest Neuroendovascular Coil market share with 40% of the overall market in 2021. The growth of this region is owing to the existence of world-class neurosurgery hospitals in the North American region. An application of neuroendovascular coils includes tumor surgery. Furthermore, the Asia-Pacific region is estimated to be the region with the fastest CAGR over the forecast period 2022-2027. This growth is owing to factors like the enormous potential for intracranial aneurysms attributed to the increasingly sedentary lifestyle in the Asia-Pacific region. The proliferating intake of alcohol, the expanding population of senior citizens and the burgeoning count of head injuries are further fuelling the progress of the Neuroendovascular Coil Market in the Asia-Pacific region.
Neuroendovascular Coil Market Drivers
Surging Applications of Neuroendovascular Coil for Treatment of Intracranial Aneurysms are Projected to Drive the Growth of Neuroendovascular Coil Market:
The prevalence of subarachnoid hemorrhage is approximated at 5 to 10 per 100,000 per year. In patients who get through the initial hemorrhage, the repeat hemorrhage rate is 15% to 20% in the earliest 2 weeks subsequent to presentation and is connected with disastrous clinical outcomes even more serious than the initial rupture. The present alternatives for aneurysm treatment are surgical clipping and since the mid-1990s, neuroendovascular coil embolization. Surgical clipping was at one time the gold standard of care, however, constant with the trend in contemporary medicine toward less-invasive processes, neuroendovascular coil embolization has steadily acquired eminence. Neuroendovascular coil embolization is presently the favored procedure for the treatment of intracranial aneurysms. The surging applications of Neuroendovascular Coil for the treatment of Intracranial Aneurysms are therefore fuelling the growth of the Neuroendovascular Coil Market during the forecast period 2022-2027.
Soaring Innovations in Coils are Expected to Boost the Growth of the Neuroendovascular Coil Industry:
Ruby® Coil is a large-volume coil that can be conveyed by way of LANTERN®, a high-flow microcatheter designated for arterial and venous embolization in the peripheral vasculature, The typical softness and 3D complex form of Ruby Coil is planned to permit the coil to heavily pack aneurysms and vessels in an assortment of clinical uses. Ruby Coil permits physicians to utilize lengthier and bigger volume coils, potentially decreasing procedural time and the total number of devices needed. Ruby Coil possesses two softness levels, Standard and Soft and can be repositioned to accomplish perfect placement. Ruby Coil LP is the most novel inclusion to the peripheral embolization platform and provides the identical technology as large volume devices of Penumbra. Ruby Coil LP is deliverable by way of low profile microcatheters .0165 – .021 (.42 – .53 mm) and is accessible in sizes as tiny as 1 mm in diameter and lengths up to 60 cm. These kinds of soaring innovations in Coils are therefore driving the growth of the Neuroendovascular Coil Industry, thereby contributing to the Neuroendovascular Coil Industry Outlook during the forecast period 2022-2027.
Neuroendovascular Coil Market Challenge
Limitations Imposed by Fluoroscopic Imaging Procedures are Hampering the Growth of the Neuroendovascular Coil Market:
Radiation-induced skin harm at the time of fluoroscopic imaging procedures has been currently attended to by The Joint Commission, which defined extended fluoroscopy leading to a cumulative peak skin dose of 15 Gy to a single field as a fluoroscopic sentinel event (FSE). Neuroendovascular processes can be connected with a soaring radiation skin dose and introduce hazards like potential FSEs. Handling these hazards is the responsibility of the interventional neuroradiologist. The interventional neuroradiologist needs to take leadership in decreasing the hazard of such events while keeping up suitable patient care. This requires instructing members of the interventional team on fluoroscopic sentinel events, utilizing best practices to diminish dose and guaranteeing that suitable hospital policies are in place and followed. These issues are thus hampering the growth of the Neuroendovascular Coil Market.
Neuroendovascular Coil Industry Outlook
Novel product launches and strategic mergers and acquisitions are key strategies adopted by players in the Neuroendovascular Coil Market. The top 10 companies in the Neuroendovascular Coil market are:
- Medtronic Plc.
- Stryker Corporation
- DePuy Synthes (Johnson & Johnson)
- Penumbra Inc.
- Terumo Corporation
- Cardinal Health
- Boston Scientific Corporation
- Cook Medical Incorporated
- Balt Extrusion
- In December 2021, the Johnson & Johnson Medical Devices Companies* declared that DePuy Synthes**, acting by way of its affiliate, Synthes GmbH, has gained the Israeli firm, OrthoSpin, Ltd. OrthoSpin establishes and produces a first-of-its-kind technology – an automated strut system – which is utilized together with DePuy Synthes MAXFRAME™ Multi-Axial Correction System, an external ring fixation system.
- In December 2020, Medtronic plc declared the U.S. commercial introduction of the Carpediem™ Cardio-Renal Pediatric Dialysis Emergency Machine. Succeeding the U.S. Food and Drug Administration's (FDA) marketing authorization, allowed earlier this year, the earliest Carpediem™ systems in the U.S. were favorably installed and are in application at Cincinnati Children's Hospital Medical Center.
- In November 2020, Medtronic plc declared that it has finished its friendly tender offer for France-based Medicrea International, a pioneer in the conversion of spinal surgery by way of artificial intelligence (AI), predictive modeling and patient-specific implants.
Report Code: CMR 1472
Report Code: CMR 1377
Report Code: CMR 0069